Ocugen Disclosed Positive Scientific Advice From The European Medicines Agency Related To The Approval Pathway For Ocu400—Modifier Gene Therapy For Broad Retinitis Pigmentosa Indication
Ocugen披露了歐洲藥品管理局關於Ocu400——寬視網膜色素變性適應症的修改基因療法的批准途徑的積極科學建議
Ocugen Disclosed Positive Scientific Advice From The European Medicines Agency Related To The Approval Pathway For Ocu400—Modifier Gene Therapy For Broad Retinitis Pigmentosa Indication
Ocugen披露了歐洲藥品管理局關於Ocu400——寬視網膜色素變性適應症的修改基因療法的批准途徑的積極科學建議
使用瀏覽器的分享功能,分享給你的好友吧